Literature DB >> 2933949

Hemodynamic effects of calcium entry-blocking agents in normal and hypertensive rats and man.

E D Frohlich.   

Abstract

To be considered ideal for the treatment of hypertension, a class of drugs should produce a maintained reduction of arterial pressure primarily through a fall in total peripheral resistance that is at least uniformly distributed through the organ circulations of the target organs of hypertensive vascular disease. Such drugs should be useful as monotherapeutic agents, should not expand the extracellular fluid compartment, should not reflexively stimulate the heart and vessels, should reverse the structural changes in the target organs without compromising function and, of course, should be relatively free of adverse effects. As a heterogeneous class of agents, the calcium entry-blocking drugs fulfill most of these criteria, although preliminary studies suggest that their effects on organ vascular resistances and on structural cardiovascular changes are highly variable. Thus, further vigorous investigation of these new agents is highly recommended.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2933949     DOI: 10.1016/0002-9149(85)90539-9

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.

Authors:  G Mikus; V Mast; C Fischer; C Machleidt; U Kuhlmann; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 2.  Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  K L Goa; E M Sorkin
Journal:  Drugs       Date:  1987-02       Impact factor: 9.546

3.  Immediate and prolonged hemodynamic effects of TA-3090 on spontaneously hypertensive (SHR) and normal Wistar-Kyoto (WKY) rats.

Authors:  T Isshiki; B L Pegram; E D Frohlich
Journal:  Cardiovasc Drugs Ther       Date:  1988-11       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.